PMC:2065877 / 904-1042 JSONTXT

{"project":"pmc-enju-pas","denotations":[{"id":"T208","span":{"begin":0,"end":4},"obj":"IN"},{"id":"T209","span":{"begin":5,"end":8},"obj":"NN"},{"id":"T210","span":{"begin":8,"end":9},"obj":"-COMMA-"},{"id":"T211","span":{"begin":10,"end":14},"obj":"NN"},{"id":"T212","span":{"begin":14,"end":15},"obj":"-COMMA-"},{"id":"T213","span":{"begin":16,"end":19},"obj":"CC"},{"id":"T214","span":{"begin":20,"end":25},"obj":"NN"},{"id":"T215","span":{"begin":26,"end":34},"obj":"NN"},{"id":"T216","span":{"begin":35,"end":38},"obj":"MD"},{"id":"T217","span":{"begin":39,"end":44},"obj":"VB"},{"id":"T218","span":{"begin":45,"end":47},"obj":"IN"},{"id":"T219","span":{"begin":48,"end":57},"obj":"JJ"},{"id":"T220","span":{"begin":58,"end":65},"obj":"NN"},{"id":"T221","span":{"begin":66,"end":68},"obj":"IN"},{"id":"T222","span":{"begin":69,"end":72},"obj":"DT"},{"id":"T223","span":{"begin":73,"end":82},"obj":"NN"},{"id":"T224","span":{"begin":83,"end":85},"obj":"IN"},{"id":"T225","span":{"begin":86,"end":100},"obj":"JJ"},{"id":"T226","span":{"begin":101,"end":102},"obj":"NN"},{"id":"T227","span":{"begin":103,"end":107},"obj":"NN"},{"id":"T228","span":{"begin":108,"end":117},"obj":"NN"}],"relations":[{"id":"R145","pred":"arg1Of","subj":"T209","obj":"T210"},{"id":"R146","pred":"arg1Of","subj":"T210","obj":"T213"},{"id":"R147","pred":"arg2Of","subj":"T211","obj":"T210"},{"id":"R148","pred":"arg1Of","subj":"T213","obj":"T212"},{"id":"R149","pred":"arg1Of","subj":"T213","obj":"T216"},{"id":"R150","pred":"arg1Of","subj":"T213","obj":"T217"},{"id":"R151","pred":"arg2Of","subj":"T215","obj":"T213"},{"id":"R152","pred":"arg1Of","subj":"T215","obj":"T214"},{"id":"R154","pred":"arg1Of","subj":"T217","obj":"T208"},{"id":"R155","pred":"arg2Of","subj":"T217","obj":"T216"},{"id":"R156","pred":"arg1Of","subj":"T217","obj":"T218"},{"id":"R157","pred":"arg2Of","subj":"T220","obj":"T218"},{"id":"R158","pred":"arg1Of","subj":"T220","obj":"T219"},{"id":"R159","pred":"arg1Of","subj":"T220","obj":"T221"},{"id":"R160","pred":"arg2Of","subj":"T223","obj":"T221"},{"id":"R161","pred":"arg1Of","subj":"T223","obj":"T222"},{"id":"R162","pred":"arg1Of","subj":"T223","obj":"T224"},{"id":"R163","pred":"arg2Of","subj":"T228","obj":"T224"},{"id":"R164","pred":"arg1Of","subj":"T228","obj":"T225"},{"id":"R165","pred":"arg1Of","subj":"T228","obj":"T226"},{"id":"R166","pred":"arg1Of","subj":"T228","obj":"T227"}],"namespaces":[{"prefix":"_base","uri":"http://kmcs.nii.ac.jp/enju/"}],"text":"that Akt, NFκB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas.\n\nAuthor Summary\n\nEp"}

{"project":"bionlp-st-ge-2016-spacy-parsed","denotations":[{"id":"T394","span":{"begin":0,"end":4},"obj":"IN"},{"id":"T395","span":{"begin":5,"end":8},"obj":"NNP"},{"id":"T396","span":{"begin":8,"end":9},"obj":","},{"id":"T397","span":{"begin":10,"end":14},"obj":"NNP"},{"id":"T398","span":{"begin":14,"end":15},"obj":","},{"id":"T399","span":{"begin":16,"end":19},"obj":"CC"},{"id":"T400","span":{"begin":20,"end":25},"obj":"JJ"},{"id":"T401","span":{"begin":26,"end":34},"obj":"NNS"},{"id":"T402","span":{"begin":35,"end":38},"obj":"MD"},{"id":"T403","span":{"begin":39,"end":44},"obj":"VB"},{"id":"T404","span":{"begin":45,"end":47},"obj":"IN"},{"id":"T405","span":{"begin":48,"end":57},"obj":"JJ"},{"id":"T406","span":{"begin":58,"end":65},"obj":"NNS"},{"id":"T407","span":{"begin":66,"end":68},"obj":"IN"},{"id":"T408","span":{"begin":69,"end":72},"obj":"DT"},{"id":"T409","span":{"begin":73,"end":82},"obj":"NN"},{"id":"T410","span":{"begin":83,"end":85},"obj":"IN"},{"id":"T411","span":{"begin":86,"end":100},"obj":"JJ"},{"id":"T412","span":{"begin":101,"end":102},"obj":"NNP"},{"id":"T413","span":{"begin":103,"end":107},"obj":"NN"},{"id":"T414","span":{"begin":108,"end":117},"obj":"NNS"},{"id":"T415","span":{"begin":117,"end":118},"obj":"."}],"relations":[{"id":"R306","pred":"mark","subj":"T394","obj":"T403"},{"id":"R307","pred":"nsubj","subj":"T395","obj":"T403"},{"id":"R308","pred":"punct","subj":"T396","obj":"T395"},{"id":"R309","pred":"conj","subj":"T397","obj":"T395"},{"id":"R310","pred":"punct","subj":"T398","obj":"T397"},{"id":"R311","pred":"cc","subj":"T399","obj":"T397"},{"id":"R312","pred":"amod","subj":"T400","obj":"T401"},{"id":"R313","pred":"conj","subj":"T401","obj":"T397"},{"id":"R314","pred":"aux","subj":"T402","obj":"T403"},{"id":"R316","pred":"prep","subj":"T404","obj":"T403"},{"id":"R317","pred":"amod","subj":"T405","obj":"T406"},{"id":"R318","pred":"pobj","subj":"T406","obj":"T404"},{"id":"R319","pred":"prep","subj":"T407","obj":"T406"},{"id":"R320","pred":"det","subj":"T408","obj":"T409"},{"id":"R321","pred":"pobj","subj":"T409","obj":"T407"},{"id":"R322","pred":"prep","subj":"T410","obj":"T409"},{"id":"R323","pred":"amod","subj":"T411","obj":"T414"},{"id":"R324","pred":"compound","subj":"T412","obj":"T413"},{"id":"R325","pred":"compound","subj":"T413","obj":"T414"},{"id":"R326","pred":"pobj","subj":"T414","obj":"T410"}],"text":"that Akt, NFκB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas.\n\nAuthor Summary\n\nEp"}

{"project":"GO-CC","denotations":[{"id":"T429","span":{"begin":103,"end":107},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"that Akt, NFκB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas.\n\nAuthor Summary\n\nEp"}

{"project":"sentences","denotations":[{"id":"T10","span":{"begin":120,"end":134},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"that Akt, NFκB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas.\n\nAuthor Summary\n\nEp"}

{"project":"events-check-again","denotations":[{"id":"T514","span":{"begin":5,"end":8},"obj":"Protein"},{"id":"T515","span":{"begin":20,"end":25},"obj":"Protein"}],"text":"that Akt, NFκB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas.\n\nAuthor Summary\n\nEp"}

{"project":"bionlp-st-ge-2016-reference-tees","denotations":[{"id":"T492","span":{"begin":5,"end":8},"obj":"Protein"},{"id":"T493","span":{"begin":10,"end":14},"obj":"Protein"},{"id":"T494","span":{"begin":20,"end":25},"obj":"Protein"}],"text":"that Akt, NFκB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas.\n\nAuthor Summary\n\nEp"}

{"project":"bionlp-st-ge-2016-reference","denotations":[{"id":"T57","span":{"begin":5,"end":8},"obj":"Protein"},{"id":"T58","span":{"begin":20,"end":25},"obj":"Protein"}],"namespaces":[{"prefix":"_base","uri":"http://bionlp.dbcls.jp/ontology/ge.owl#"}],"text":"that Akt, NFκB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas.\n\nAuthor Summary\n\nEp"}

{"project":"bionlp-st-ge-2016-uniprot","denotations":[{"id":"T249","span":{"begin":5,"end":8},"obj":"P31749"},{"id":"T250","span":{"begin":5,"end":8},"obj":"P31751"},{"id":"T251","span":{"begin":5,"end":8},"obj":"Q9Y243"},{"id":"T252","span":{"begin":20,"end":25},"obj":"P40763"}],"namespaces":[{"prefix":"_base","uri":"http://www.uniprot.org/uniprot/"}],"text":"that Akt, NFκB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas.\n\nAuthor Summary\n\nEp"}

{"project":"test2","denotations":[{"id":"T36","span":{"begin":5,"end":8},"obj":"Protein"},{"id":"T37","span":{"begin":20,"end":25},"obj":"Protein"}],"text":"that Akt, NFκB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas.\n\nAuthor Summary\n\nEp"}